Physician profile
Aparna Raikar
NPI 1689091837
$739.23
in general payments reported to CMS, 2019-2025
12 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.71 · 2022: $121 · 2023: $312 · 2024: $42.96 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $149.75 | 2022-2023 | Tirosint, Licart |
| Beta Bionics, INC. | $144.73 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $144.35 | 2023-2024 | Wegovy |
| Lilly USA, LLC | $116.87 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $46.20 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $24.08 | 2025 | |
| Hologic Sales and Service, LLC | $23.60 | 2024 | Aptima |
| Sanofi-Aventis U.S. LLC | $21.14 | 2023 | |
| Pfizer INC. | $18.37 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.12 | 2023 | Jardiance |
| Currax Pharmaceuticals LLC | $16.42 | 2025 | Contrave |
| Abbvie INC. | $15.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aparna Raikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.